NDTV Profit's special research section collates quality and in-depth equity and economy research reports from across India's top brokerages, asset managers and research agencies. These reports offer NDTV Profit's subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
-
Indian Markets Turning Corner After Two Tough Years, Says Sandeep Tandon -
NDTV Profit Ignite 2026: Experts See Opportunity In Equities, Stay Bullish For Long-Term -
Buy Right, Sit Tight Does Not Work for Individual Stocks, Says Dinshaw Irani -
'Worst Is Behind': Quant MF Sees Market Bottom, Flags 'Extreme Euphoria' In Midcaps -
India's Mutual Fund Industry Could Become A $1 Trillion Opportunity, Say Fund Managers -
'Foreign Investors Are Baraatis': Raamdeo Agrawal's Take On LTCG Tax -
Stay Invested Through Market Cycles: Raamdeo Agrawal at NDTV Profit Ignite -
Ramesh Damani Remains Bullish On India For Next 20-30 Years, Sees Bargains Amid Market Weakness -
CAS Came After A Long Consultation Process: SEBI Chairman Tuhin Kanta Pandey AT NDTV PROFIT IGNITE -
Aim To Cut FPI Onboarding Time From Mth To Five Days: SEBI Chairman Tuhin Kanta Pandey AT NDTV PROFI
Gland Pharma Ltd. delivered a stronger‑than‑expected performance in Q3 FY26, reporting a 6% beat in revenue, 14% beat in Ebitda, and 19% beat in PAT versus Motilal Oswal's estimates.
Also Read | Layoffs Are Rising In Tech, But These Skills Are Helping People Unlock Better Pay
The outperformance was driven by Ebitda break‑even at Cenexi, solid volume growth in the core business, and favorable currency movements during the quarter.
The brokerage highlighted that US revenue growth has been on an improving trajectory for the past three quarters, supported by product launches, higher off-take of base molecules, and currency depreciation.
While Gland Pharma's partner is yet to receive approval for g-Dalbavancin in the US market, traction has started following regulatory approval in the EU market. Further, scale-up in certain products from the Cenexi portfolio has led to healthy growth in the EU segment.
Comprehensive initiatives enabled Cenexi to deliver superior performance for the quarter.
The brokerage values Gland Pharma at 28 times 12‑month forward earnings, arriving at a revised target price of Rs 2,050, and reiterates its Buy rating.
Click on the attachment to read the full report:
WeWork Shares May Rally 52%, Says ICICI Securities On Robust Q3 Numbers— Check Revised Target Price
DISCLAIMER
This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.
